Equities analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report $420.74 million in sales for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Jazz Pharmaceuticals PLC’s earnings. The highest sales estimate is $426.72 million and the lowest is $412.64 million. Jazz Pharmaceuticals PLC reported sales of $374.18 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.4%. The company is scheduled to announce its next earnings report on Tuesday, November 14th.

On average, analysts expect that Jazz Pharmaceuticals PLC will report full-year sales of $420.74 million for the current financial year, with estimates ranging from $1.63 billion to $1.67 billion. For the next fiscal year, analysts expect that the firm will post sales of $1.89 billion per share, with estimates ranging from $1.81 billion to $2.06 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. During the same period last year, the company earned $2.67 earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year.

JAZZ has been the subject of a number of research analyst reports. Wells Fargo & Company restated an “outperform” rating and set a $177.00 target price (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub cut Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Vetr upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a report on Tuesday, June 6th. Piper Jaffray Companies restated an “overweight” rating and set a $182.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, Cowen and Company restated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $180.96.

COPYRIGHT VIOLATION WARNING: “$420.74 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/09/420-74-million-in-sales-expected-for-jazz-pharmaceuticals-plc-jazz-this-quarter.html.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at 152.28 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The company has a 50-day moving average of $150.15 and a 200-day moving average of $149.45. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of 23.46 and a beta of 1.13.

In other news, Director Patrick G. Enright sold 351 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $148.40, for a total transaction of $52,088.40. Following the sale, the director now owns 1,717 shares of the company’s stock, valued at approximately $254,802.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $150.65, for a total value of $30,130.00. Following the sale, the executive vice president now directly owns 22,223 shares in the company, valued at approximately $3,347,894.95. The disclosure for this sale can be found here. Insiders have sold a total of 7,917 shares of company stock worth $1,223,227 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Toronto Dominion Bank increased its position in Jazz Pharmaceuticals PLC by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares during the period. US Bancorp DE increased its position in Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the period. Envestnet Asset Management Inc. increased its position in Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the period. World Asset Management Inc acquired a new position in Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Finally, Gargoyle Investment Advisor L.L.C. acquired a new position in Jazz Pharmaceuticals PLC during the second quarter worth approximately $206,000. 88.24% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals PLC (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.